Courier Capital LLC lifted its stake in shares of Sanofi (NYSE:SNY) by 0.9% during the third quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 24,134 shares of the company’s stock after purchasing an additional 220 shares during the quarter. Courier Capital LLC’s holdings in Sanofi were worth $1,189,000 as of its most recent SEC filing.
Other hedge funds and other institutional investors have also made changes to their positions in the company. Prospera Financial Services Inc bought a new position in Sanofi in the 3rd quarter worth about $27,000. Princeton Global Asset Management LLC increased its stake in Sanofi by 101.4% in the 3rd quarter. Princeton Global Asset Management LLC now owns 582 shares of the company’s stock worth $29,000 after acquiring an additional 293 shares during the last quarter. Northwest Investment Counselors LLC bought a new position in Sanofi in the 3rd quarter worth about $39,000. SRS Capital Advisors Inc. increased its stake in Sanofi by 47.1% in the 2nd quarter. SRS Capital Advisors Inc. now owns 824 shares of the company’s stock worth $42,000 after acquiring an additional 264 shares during the last quarter. Finally, Berman Capital Advisors LLC increased its stake in Sanofi by 37.5% in the 2nd quarter. Berman Capital Advisors LLC now owns 902 shares of the company’s stock worth $45,000 after acquiring an additional 246 shares during the last quarter. Institutional investors and hedge funds own 7.04% of the company’s stock.
A number of equities analysts have weighed in on SNY shares. SVB Leerink lowered Sanofi to a “market perform” rating in a research note on Tuesday, August 18th. Stifel Nicolaus lowered Sanofi from a “buy” rating to a “hold” rating in a research report on Wednesday, August 19th. Zacks Investment Research upgraded Sanofi from a “hold” rating to a “buy” rating and set a $53.00 price objective on the stock in a research report on Monday, October 19th. JPMorgan Chase & Co. restated an “overweight” rating on shares of Sanofi in a report on Friday, October 30th. Finally, Berenberg Bank began coverage on Sanofi in a report on Tuesday, September 29th. They set a “hold” rating for the company. Six research analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average target price of $55.67.
SNY opened at $50.49 on Tuesday. The stock has a market cap of $126.88 billion, a PE ratio of 16.19, a PEG ratio of 2.41 and a beta of 0.67. The company has a quick ratio of 0.85, a current ratio of 1.22 and a debt-to-equity ratio of 0.40. The business has a 50 day moving average of $49.59 and a 200-day moving average of $50.31. Sanofi has a 52 week low of $37.62 and a 52 week high of $55.00.
Sanofi (NYSE:SNY) last released its earnings results on Thursday, October 29th. The company reported $1.07 EPS for the quarter, missing the Zacks’ consensus estimate of $1.09 by ($0.02). The firm had revenue of $9.48 billion during the quarter, compared to analysts’ expectations of $9.65 billion. Sanofi had a net margin of 12.20% and a return on equity of 18.18%. The company’s revenue for the quarter was down .2% compared to the same quarter last year. During the same quarter in the previous year, the business earned $1.92 EPS. Equities analysts anticipate that Sanofi will post 3.1 EPS for the current year.
Sanofi provides therapeutic solutions worldwide. It offers Cerezyme and Cerdelga for Gaucher, Myozyme and Lumizyme for Pompe, Fabrazyme for Fabry, and Aldurazyme for mucopolysaccharidosis Type 1; and Aubagio and Lemtrada for multiple sclerosis. It also provides Dupixent for atopic dermatitis; Kevzara for rheumatoid arthritis; Eloctate and Alprolix to treat hemophilia; and Cablivi to treat acquired thrombotic thrombocytopenic purpura.
Featured Article: What does the Producer Price Index (PPI) tell investors?
Want to see what other hedge funds are holding SNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sanofi (NYSE:SNY).
Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.